<p>Randox Laboratories and Qnostics have today announced that they have entered into a strategic partnership.</p><p>The partnership will provide Randox Laboratories with access to the Qnostics molecular range of products for sales and distribution purposes, complementing the established Randox Laboratories portfolio.</p><p>Access to the Randox Laboratories commercial capabilities will enhance Qnostics&amp;rsquo; market penetration, whilst also maintaining their presence as an independent provider of molecular quality controls and custom services.</p><p>MD of Randox Laboratories, Dr Peter FitzGerald said;</p><p>“We are delighted to have agreed a strategic partnership with Qnostics, an arrangement we see as mutually beneficial.  We look forward to working together to strengthen the molecular service we provide to our global markets whilst enhancing the Qnostic brand and market penetration.”</p><blockquote class="style-3"><p>“We are delighted to have agreed a strategic partnership with Qnostics, an arrangement we see as mutually beneficial.  We look forward to working together to strengthen the molecular service we provide to our global markets whilst enhancing the Qnostic brand and market penetration.”</p></blockquote><p>Dr Frank Opdam, Head of Commercial of Qnostics said;</p><p>“We believe this is an ideal partnership. We look forward to working with Randox Laboratories and the growth that will result from the global access this partnership will provide to Qnostics for its expanding range of molecular quality control products.”</p><p>Contact Information</p><p>For further details please contact:</p><p>Qnostics</p><p>Email ID: info@qnostics.com</p><p>Randox Laboratories Ltd</p><p>Email ID: randoxpr@randox.com</p>